Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Castration-Resistant Prostate Cancer: early-phase trial registry
45 of 70 indexed Metastatic Castration-Resistant Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #198 of 28,707 conditions by registered trial count.
70 US clinical trials · 45 currently recruiting · #198 of 28,707 conditions by registered trial count
Metastatic Castration-Resistant Prostate Cancer: 70 US clinical trials tracked, 45 recruiting.
Metastatic Castration-Resistant Prostate Cancer is the subject of 70 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 60 in Phase 1-2 (earlier-stage). The most active sponsor is University of Utah, running 5 of these trials.
Enrollment posture brief
Registry condition metastatic-castration-resistant-prostate-cancer
OPEN 45 | RECR 64% | LATE 9 | EARLY 60 | RANK #198 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Cardiac Rehabilitation (64% recruiting · 14 trials)
Metastatic Castration-Resistant Prostate Cancer lists 45 open slots (64% of 70 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Castration-Resistant Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Castration-Resistant Prostate Cancer is recruiting above its size-band peers.
45 of 70 indexed trials (64.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Castration-Resistant Prostate Cancer trials is spread across many organizations.
University of Utah accounts for 5 of 70 trials (7.1%). 48 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Castration-Resistant Prostate Cancer enrolment sits around 72 participants.
Median target enrolment is 72 among the 70 trials that report a genuine target (sentinel values excluded). 41 of those (58.6%) plan for fewer than 100 participants.
-
Metastatic Castration-Resistant Prostate Cancer research is mostly interventional.
69 interventional and 1 observational studies make up this index (98.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
70 total, page 1 of 2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Merck Sharp & Dohme
NCT02861573
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Celgene
NCT06764485
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
NCT06629779
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
NCT07213674
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
NCT06691984
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06520345
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
NCT05125016
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Janux Therapeutics
NCT05519449
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Global Development
NCT07005154
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT07288359
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
NCT04986423
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Global Development
NCT04729114
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
K36 Therapeutics
NCT07103018
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
AbbVie
NCT06318273
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
NCT06067841
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Novartis Pharmaceuticals
NCT06531499
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Hoffmann-La Roche
NCT07287150
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fusion Pharmaceuticals
NCT06402331
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
NCT06879041
64Cu-GRIP B in Patients With Advanced Malignancies
Rahul Aggarwal
NCT05888532
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics
NCT05413850
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Kyntra Bio
NCT06842498
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune
NCT06533644
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07142551
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
NCT07244341
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
Syntrix Biosystems
NCT06228053
Study With [225Ac]Ac-FL-020 in mCRPC Participants
Full-Life Technologies
NCT06492122
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06922318
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
NCT05766371
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Case Comprehensive Cancer Center
NCT06738303
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
NCT07189403
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
NCT07025512
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT06303713
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
University of Utah
NCT05613894
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
University of Utah
NCT06568562
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
NCT06972628
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
NCT06099093
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
NCT06193486
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
NCT06100705
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
FutureChem
NCT05458544
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
University of Utah
NCT06029998
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
NCT07476001
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
NCT03732820
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
NCT04647526
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT03845166
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer
NCT06052306
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
OncoC4
NCT05682443
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 27 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Castration-Resistant Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Castration-Resistant Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Castration-Resistant Prostate Cancer page
70 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Metastatic Castration-Resistant Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Utah sponsors the most Metastatic Castration-Resistant Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See University of Utah's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Castration-Resistant Prostate Cancer condition card totals 70 registered trials; most-linked intervention Enzalutamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.